Single-agent gemeitabine versus cisplatln-etoposlde: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer

Annals of Oncology

Volumn 8, Issue 6, 1997, Pages 525-529

  Manegold, C ^a,o   Bergman, B ^b   Chemaissani, A ^c   Dornoff, W ^d   Drings, P ^e   Kellokumpulehtinen, P ^f   Liippo, K ^g   Mattson, K ^h   Pawel, J ⁱ   Ricci, S ^j   Sederholm, C ^k   Stahel, R A ^l   Wagenius, G ^m   Walree, N ⁿ   Huinink, W ^m  

^a Thwraxklinik Heidelberg   (Germany)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c KRANKENHAUS MERHEIM   (Germany)

^d Mutterhaus der Borromäeriitnen   (Germany)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h Zentralkrankenhaus Garmany   (Germany)

ⁱ UNIVERSITY OF PISA   (Italy)

^j LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^k Universitätsspinil Zürich   (Switzerland)

^l UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^m ST ANTONIUS HOSPITAL   (Netherlands)

ⁿ NETHERLANDS CANCER INSTITUTE   (Netherlands)

^o Thcraxklinik Department of Medical Oncology   (Germany)

more..

Author keywords

Cispiatin; Etoposide; Gemcitabine; Non small cell lung cancer; Randomised phase II study

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CISPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; ETOPOSIDE; GEMCITABINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 0031157857     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008207731111     Document Type: Article

References (30)

1. Non-srnall-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909.
2. Abratt RP, Bezwoda WR, Falkson G et al. Efficacy and safety profile of gemcitabine in non-small-ccll lung cancer: A phase II study. J Clin Oncol 1994; 12: 1535-40.
3. Andersen H, Lund B. Bach Fet al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. .1 Clin Oncol 1994; 12: 1S21-6.
4. Gatzemeier U. Shepherd FA. Le Chevalier T et al. Activity of gemcitabine in patients with non-small-cell lung cancer: A multicenter extended phase II study. Etir J Cancer 1996; 32 (2): 243-8.
5. Fossdla FV. Lippman SM. Shin DM et al. Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapj'-naive patients with advanced nonsmall-ceil lung cancer. J Clin Oncol 1997; 15: 310-6.
6. Crino L. Scagliotti G. Marangolo M et al. Cisplatin gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1997; 15: 297-303.
7. Abratt RP. Bezwoda WR, Goedhals L et al. Weekly gemcitabine with monthly cispiatin: Effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 1997: 15: 744-9.
8. Ardizzoni A. Martin C. Gemcitabine toxicity profile and efficacy unaffected by age in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 1994: 5 (Suppl 8): 60 (Abstr P295).
9. Pocock SJ. Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975: 31: 103-15.
10. Crino L, Tonato M. Darwish S et al. A randomised trial of 3 cispiatin containing regimens in NSCLC. A study of the Lmbrian Lung Cancer Grcup. Cancer Chemotherapy Pharmacci 1990: 26: 52-6.
11. Ruckdesehel JC. The role of standard dose etoposide in the management of NSCLC. Semin Oncol 1992: 10: 39-44.
12. Bonorni P. Finkelstein D. Chang A. Phase II trial of acivicin versus etoposide-cisplatin in non-small-cell lung cancer. An Eastern Cooperative Oncology Group study. Arn J Clin Oncol 1994: 17: 215-7.
13. Dhingra HM. Valdivicso M. Carr DT e; al. Randomised trial of three combinations of cispiatin with \indesine and 'or VP-16 in ;he treatment of advanced NSCLC J Clin Oncol 1985; 3: 176 83.
14. Hainsworih JD. Johnson DH. Chemotherapy of advanced NSCLC: A randomised trial of three cisplatin-based chemotherapy regimens. Am .1 Clin OncoS 1989: 12: 345-9.
15. Klasiersky j. Sculier JP, Lacroix H et al. A randomised study comparing cisplaim or carbcplatin with etoposide in patients with advanced NSCLC. EORTC protocol 07861. J Clin Oncol 1990: 8: 1556 62.
16. Ruckdeschel JC. Finkelstein DH. Ettinger DS et al. A randomised trial of the four most active regimens for metastatic NSCLC. J Clin Oncol 1986: 4: 14-21.
17. Weick JK. Crowley J. Natale RB et al. A randomised trial of rive cispidtin containing regimens in patients with metastatic NSCLC. A Southwest Oncology Group Study, j Clin Oncol 1991: 9: 1157-62.
18. Klastersky J. Sculier JP. Ravez P ci al. A randomised study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced NSCLC. J Clin Oncoi I9S6; 4: 17SO-6.
19. Bonomi PD. Finkelstein DM. Ruckdeschel JC et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602 13.
20. Slevin VIL, Stubbs L, Plant HJ et al. Attitude to chemotherapyComparing views of patients with cancer with those of doctors, nurses and general public. BMJ 1990; 300: 1458-60.
21. Einhorn LH. Loehrer PJ. Williams SD et al. Random prospective study of vindesine versus vindesine plus cisplatin. plus mitomycin in advanced non-small-cell lung cancer. J Clin Oncol 1986: 4: 1037-43.
22. Sorensen B. Hansen HH. Dambernowsky Pet al. Chemotherapy for adcnocarcinoma of the iung (WHO HI): A randomised study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs. J Clin Oncol 1987; 5: 1159-77.
23. Klastersky J. Sculier JP. Bureau G et al. Cispiatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1989: 7: 1087 92.
24. Rosso R. Salvati F. Ardizzoni A et al. Etoposide versus etoposide plus high-dose cispif.tin in the management of advanced nonsmall-cell lung cancer. Cancer 1990; 66: 130-4.
25. Kawahara M. Furuse K. Nagohesa K e-. al. A randomized study of cisplatin versus cisplatin plus vindesine for non-small-cell lung cancer. Cancer 1991: 68: 714-9.
26. Veeder MH. Jett JR. Su JO et ai. A phase III trial of mitomycin C alone versus mitomycin C, vinbiastine and cisplatin for mctastatic squamous cell lung cancer. Cancer 1992: 70: 2281-6.
27. Depierrc A. Lc Beau B. Chasting C et al. Results of a phase 111 randomized study of vinorelbine-cisplatin in non-smail-cell lung cancer. Proc Am Soc Clin Oncol 1993: 12: 340.
28. Giaccone G. Splinter T. Fester J et al. Cisplatin combined with teniposide improves response and survival over VM alone in nonsmall-ceil lung cancer: A randomized trial of the EORTC Lung Cancer Cooperative Group. Proc Am Soc Clin Oncol 1993; 12: 331.
29. Le Chevalier T. Brisgand D, Doulliard JY et al. Randomized study of vinorelbine and cispiatin versus vindesine and cispkain versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-7.
30. Van Meerbeck J. Debruyne C. Postrnus PE et ai. Sequential phase II studies with paclitaxel and gemcitabinc in malignant pleurai mesothelionia. Eur Rcsp J 1996; 9 (Suppl 23): 400s.